We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

81 hedge funds and large institutions have $339M invested in Enanta Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,333% more call options, than puts

Call options by funds: $412K | Put options by funds: $12K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

158% more capital invested

Capital invested by funds: $132M → $339M (+$208M)

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

23% more funds holding

Funds holding: 66 → 81 (+15)

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

Holders
81
Holders Change
+15
Holders Change %
+22.73%
% of All Funds
2.34%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
29
Increased
25
Reduced
21
Closed
13
Calls
$412K
Puts
$12K
Net Calls
+$400K
Net Calls Change
+$400K

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$56M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$42.5M
3
EAM
Eagle Asset Management
Florida
+$19.2M
4
CCM
Consonance Capital Management
New York
+$14.6M
5
ICRM
Insight Capital Research & Management
California
+$7.51M

Top Sellers

1
Franklin Resources
Franklin Resources
California
-$8.16M
2
AP
AlpInvest Partners
Netherlands
-$4.49M
3
SM
Sabby Management
Florida
-$3.12M
4
Millennium Management
Millennium Management
New York
-$2.93M
5
Barclays
Barclays
United Kingdom
-$2.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$2.03M +$285K +7,844 +18%
SCM
27
Sarissa Capital Management
Connecticut
$2M +$1.82M +50,000 New
BIT
28
BlackRock Institutional Trust
California
$1.61M -$463K -12,742 -24%
RFC
29
Russell Frank Company
Washington
$1.59M +$89.4K +2,460 +6%
ACM
30
Apex Capital Management
Ohio
$1.55M +$1.41M +38,755 New
GTC
31
Ghost Tree Capital
New York
$1.4M +$1.27M +35,000 New
DILH
32
Dai-ichi Life Holdings
Japan
$1.39M +$1.27M +34,842 New
BLM
33
Bennett Lawrence Management
New York
$1.36M +$1.24M +34,005 New
Ameriprise
34
Ameriprise
Minnesota
$1.21M -$23.9K -657 -2%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$1.2M +$312K +8,596 +40%
PI
36
Putnam Investments
Massachusetts
$1.04M +$942K +25,929 New
Invesco
37
Invesco
Georgia
$1.02M +$929K +25,562 New
Deutsche Bank
38
Deutsche Bank
Germany
$751K +$585K +16,104 +598%
AI
39
Analytic Investors
California
$689K -$9.95K -274 -2%
SO
40
STRS Ohio
Ohio
$664K +$287K +7,900 +91%
Asset Management One
41
Asset Management One
Japan
$525K +$317K +8,714 +182%
NI
42
Numeric Investors
Massachusetts
$488K -$1M -27,600 -69%
ARC
43
Absolute Return Capital
Massachusetts
$472K +$429K +11,815 New
Connor, Clark & Lunn Investment Management (CC&L)
44
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$441K +$363K +10,000 New
NFA
45
Nationwide Fund Advisors
Ohio
$433K +$7.26K +200 +2%
CS
46
Credit Suisse
Switzerland
$424K +$34K +937 +10%
BIM
47
BlackRock Investment Management
Delaware
$413K +$7.55K +208 +2%
Charles Schwab
48
Charles Schwab
California
$313K +$6.54K +180 +2%
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
$280K +$254K +6,997 New
Massachusetts Financial Services
50
Massachusetts Financial Services
Massachusetts
$267K +$242K +6,670 New
1
2
3 4

ENTA Hedge Fund Activity: Q1 2014 in Review

81 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2014, worth a combined $339M — up 158% from $132M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ENTA positions and 13 closed out — a net gain of 16 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $56M. The largest seller was Franklin Resources, exiting entirely with an estimated $8.16M sold.

  • 81 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2014, up from 66 in Q4 2013.
  • Funds reported $339M of Enanta Pharmaceuticals stock for Q1 2014, up 158% quarter-over-quarter.
  • 29 funds opened new Enanta Pharmaceuticals positions in Q1 2014 and 13 closed out, a net change of +16 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2014 was RA Capital Management, an estimated $56M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2014 was Franklin Resources, an estimated $8.16M sold.

Based on aggregated 13F filings for Q1 2014.